FOR IMMEDIATE RELEASE NuSep Half Year Profit Presentation SYDNEY, AUSTRALIA 17 th February, 2010 NuSep (ASX: NSP) is pleased to provide an audio and powerpoint broadcast with Mr John Manusu and Dr Hari Nair, Executive Chairman and Managing Director in a presentation titled "NuSep Announces Maiden Operational Profit - Mr John Manusu, Executive Chairman, and Dr Hari Nair, Managing Director". To listen: copy the following details into your web browser: brr.com.au/event/64173 The presentation details are as follows: NuSep Announces Maiden Operational Profit - Mr John Manusu, Executive Chairman, and Dr Hari Nair, Managing Director, Presented by Mr John Manusu and Hari Nair, Executive Chairman and Managing Director, Wed, 17 Feb 2010 09:15AM AEST The powerpoint presentation is attached to this announcement. About NuSep NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA. With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification. NuSep s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia. NuSep Products: Gels NuSep manufactures and sells precast gels including the innovative igels, with a 2 year shelf life. Separation Instruments NuSep has developed two unique biological separation instruments, the ProteomeSep and the SpermSep. The ProteomeSep separates biological samples for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and recently completed a successful clinical trial. Biological Products NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin. For more information about NuSep please visit the company s website www.nusep.com NuSep Ltd 324 Burns Bay Rd Lane Cove NSW 2066 Postal Address P.O. Box 823 Lane Cove NSW 1595 Contact Details Telephone +61 2 8977 9000 Facsimile +61 2 8977 9099 Email info@nusep.com Web www.nusep.com ABN 33 120 047 556
2 Contact: Prakash Patel Chief Financial Officer & Company Secretary +61 2 8197 3377 prakash.patel@nusep.com
Maiden Profit Half Year Results 31 December 2009 A Turn Around Story
Important Notice This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.
Profile NuSep is a Life Science Toolbox Company that develops products for the Proteomics and IVF markets NuSep s products are based on its platform PrIME technology
NuSep s s Product Markets IVF Consumables Market, $50M Gels Market, $100M Mass Spec Separations Market, $60M NuSep Products address existing niche markets
Appendix 4D Six Months to 31 Dec 2009 31 Dec 2009 31 Dec 2008 % Change $ 000 $ 000 Revenue $880 862 + 2% Gross Margin $385 $262 +46% Net Loss $182 $1,952 Down 91% EBITDA Profit $90 $1,770 +105% Total Equity $2,604 $398 +753%
Gross Profit 400 350 300 250 200 150 100 50 0 $385k $262k 2009 2008 Gross Profit has increased from 30% to 43% of Sales. Further Increases projected as NUView sales increase
Maiden EBITDA Profit 500 0 $90k -500-1000 -1500-2000 -$1,770k 2009 2008 Maiden EBITDA Profit EBITDA increased from -$1770k to +$90k. This represents a $1.8m improvement.
Total Equity 3000 2500 $2,600k 2000 1500 1000 500 0-500 -1000 -$398k Dec 2009 June 2009 Total Equity improved by $3m in the 6 months to 31 Dec 09 Total Equity increased by 753%
FY 2010 Forecast On Track Revenue $4m Gross Margin $2.5m Net Profit $0.5m EBITDA $0.56m